XB
Xiushi Biopharma (Nantong) Co., Ltd.
CDMO · Nantong, China
Overview
Xiushi Biopharma was established in Nantong in 2020 and focuses on making peptides by biosynthesis (recombinant fermentation and refolding) at large scale. It offers peptide CMC development, drug substance supply and discovery services, with a research and pilot centre over 10,000 m2 and a manufacturing base over 20,000 m2. Its Nantong and Rudong entities hold active US Type II DMFs for Semaglutide, Tirzepatide (3 DMFs in total).
Capabilities
- Biosynthetic peptide manufacturing
- Peptide CMC development
- Peptide drug substance supply
- Peptide discovery
Quality signals
| GMP evidence | Not found |
|---|---|
| Certificates of analysis | Not found |
| Third-party testing | Not found |
| ISO certification | Not found |
| Makes own product | Yes, in-house production |